PHAR vs. HCM, EWTX, MIRM, AMRX, KYMR, GMTX, PTGX, MESO, CNTA, and BHC
Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include HUTCHMED (HCM), Edgewise Therapeutics (EWTX), Mirum Pharmaceuticals (MIRM), Amneal Pharmaceuticals (AMRX), Kymera Therapeutics (KYMR), Gemini Therapeutics (GMTX), Protagonist Therapeutics (PTGX), Mesoblast (MESO), Centessa Pharmaceuticals (CNTA), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry.
Pharming Group vs.
Pharming Group (NASDAQ:PHAR) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.
HUTCHMED has a net margin of 0.00% compared to Pharming Group's net margin of -6.09%. HUTCHMED's return on equity of 0.00% beat Pharming Group's return on equity.
In the previous week, HUTCHMED had 2 more articles in the media than Pharming Group. MarketBeat recorded 3 mentions for HUTCHMED and 1 mentions for Pharming Group. Pharming Group's average media sentiment score of 1.11 beat HUTCHMED's score of 0.91 indicating that Pharming Group is being referred to more favorably in the media.
Pharming Group has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
HUTCHMED has higher revenue and earnings than Pharming Group.
Pharming Group presently has a consensus price target of $27.00, suggesting a potential upside of 201.34%. HUTCHMED has a consensus price target of $19.00, suggesting a potential upside of 18.15%. Given Pharming Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Pharming Group is more favorable than HUTCHMED.
HUTCHMED received 295 more outperform votes than Pharming Group when rated by MarketBeat users. Likewise, 66.32% of users gave HUTCHMED an outperform vote while only 64.52% of users gave Pharming Group an outperform vote.
0.0% of Pharming Group shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
HUTCHMED beats Pharming Group on 12 of the 16 factors compared between the two stocks.
Get Pharming Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pharming Group Competitors List
Related Companies and Tools
This page (NASDAQ:PHAR) was last updated on 2/21/2025 by MarketBeat.com Staff
Free PHAR Stock Alerts